常见化疗药物对免疫酶促反应的干扰效应

目的: 探讨常见化疗药物对标记酶免疫分析技术的影响。方法: 将干扰药物烷化剂（环磷酰胺），抗代谢药（阿糖胞苷、氟尿嘧啶、吉西他滨、地西他滨），抗肿瘤抗生素（依托泊苷），抗肿瘤植物成分药（长春新碱、紫杉醇、多西他赛），其他抗肿瘤药（顺铂、奥沙利铂、卡铂、奈达铂、伊立替康），抗肿瘤靶向药（硼替佐米、郝赛汀、培美曲塞二钠）分别加入辣根过氧化物酶（HRP）+ 四甲基联苯胺（TMB）反应体系中，用酶标仪测光密度值；同时加入碱性磷酸酶（ALP）+ 3-(2′-螺旋金刚烷)-4-甲氧基-4-(3″-磷酰氧基)苯-1,2-二氧杂环丁烷（AMPPD）反应体系中，用化学发光仪测相对发光强度值。结果： 在HRP酶标反应体系中，与对照组相比，吉西他滨、硼替佐米、多西他赛、紫杉醇、氟尿嘧啶、依托泊苷均显示了不同程度的负向干扰（P<0.05或P<0.01），其中，吉西他滨、多西他赛、紫杉醇、氟尿嘧啶、依托泊苷的干扰效应均呈剂量依赖性。在ALP酶标反应体系中，与对照组相比，硼替佐米、多西他赛、紫杉醇、依托泊苷、伊立替康、地西他滨、培美曲塞二钠均显示了不同程度的负向干扰（P<0.05或P<0.01），其中，多西他赛、紫杉醇、伊立替康、地西他滨、培美曲塞二钠的干扰效应均呈剂量依赖性。在两种酶反应体系中，多西他赛和紫杉醇在人体血样药物峰浓度时对HRP和ALP酶活性仍具有明显抑制作用。结论： 多西他赛、紫杉醇两种化疗药物对HRP和ALP免疫酶促反应体系存在明显干扰作用。

Interfering effects of common chemotherapeutic drugs on immunoenzymatic reaction system

Objective: To explore the interfering effects of common chemotherapy drugs on enzyme labeled immunoassay. Methods: Interfering drug alkylating agents (cyclophosphamide), antimetabolites (cytarabine, fluorouracil, gemcitabine, decitabine), anti tumor antibiotics (etoposide), anti tumor plant component drugs (vincristine, paclitaxel and docetaxel), other anti tumor drugs (cisplatin, oxaliplatin, carboplatin, nedaplatin and irinotecan) and anti tumor targeted drugs (bortezomib, hoxetine, pemetrexed disodium) were added into the horseradish peroxidase (HRP)+tetramethylbenzidine (TMB) reaction systems to measure the optical density value with a microplate reader; and the alkaline phosphatase (ALP)+3-(2′-Spiraladamantane) 4 methoxy 4 (3″ phosphoryloxy) benzene-1,2-dioxetane (AMPPD) reaction system to measure the relative luminous intensity with a chemiluminescence instrument. Results: Compared with the control group, in the HRP enzyme-labeled reaction system, all of gemcitabine, bortezomib, docetaxel, paclitaxel, fluorouracil and etoposide produced different degrees of negative interference (P<0.05 or P<0.01). Among them, the interference effects of gemcitabine, docetaxel, paclitaxel, fluorouracil and etoposide were all dose-dependent. In the ALP enzyme-labeled reaction system, compared with the control group, all of bortezomib, docetaxel, paclitaxel, etoposide, irinotecan, decitabine and pemetrexed disodium produced different degrees of negative interference (P<0.05 or P<0.01). Among them, the interference effects of docetaxel, paclitaxel, irinotecan, decitabine, and pemetrexed disodium were all dose dependent. In the two enzyme reaction systems, docetaxel and paclitaxel still had interference effects at the peak concentration of human blood. Conclusion: Docetaxel and paclitaxel had obvious interference effects on HRP and ALP-labeled immune reaction system.